Results 171 to 180 of about 77,108 (288)

Emerging options for the treatment of melanoma – focus on ipilimumab

ImmunoTargets and Therapy, 2014
Claire Roddie, Karl S Peggs UCL Cancer Institute, Department of Hematology, London, UK Abstract: Ipilimumab is a fully human immunoglobulin subclass G1 anticytotoxic-T-lymphocyte-antigen-4 monoclonal antibody.
Roddie C, Peggs KS
doaj  

A case of diverse psychiatric and functional impairments following immune checkpoint inhibitor therapy

Psychiatry and Clinical Neurosciences Reports, Volume 5, Issue 1, March 2026.
Abstract Background Immune checkpoint inhibitors (ICIs) can cause a range of immune‐related adverse events (irAEs), including rare neuropsychiatric complications. However, these events often present with diverse and non‐specific symptoms, making diagnosis difficult.
Takako Ikegami, Ryoichi Sadahiro, Junji Yamaguchi, Eri Nishikawa, Saho Wada, Tatsuto Terada, Rika Nakahara, Hiromichi Matsuoka   +7 more
wiley   +1 more source

Deep Dermal and Subcutaneous Deposits in Thin Melanoma: A Cautionary Tale

Journal of Cutaneous Pathology, Volume 53, Issue 3, Page 224-229, March 2026.
ABSTRACT Melanoma microsatellites are peritumoral metastatic deposits and surrogates for potentially aggressive biological behavior. Their presence indicates clinical stage III disease. They are rarely reported in association with thin primary tumors (< 1.0 mm, pT1).
Angela Cheng, Jennette Gruchy, Ariel Burns, Richard Langley, Jason Williams, Ryan DeCoste   +5 more
wiley   +1 more source

Lichen Planopilaris Induced by Checkpoint Inhibitors: A Systematic Review

International Journal of Dermatology, EarlyView.
Niyoosha Yoosefi, Adrian Tabari, Jeffrey Donovan   +2 more
wiley   +1 more source

Comparative analysis of the characteristics and trends of adverse drug reaction reports from patients in Japan and the Japanese Adverse Drug Event Report database

British Journal of Clinical Pharmacology, Volume 92, Issue 2, Page 515-524, February 2026.
Aims Spontaneous reporting of adverse drug reactions (ADR) after a product has reached the market is essential for drug safety. This study analysed patient ADR reports and compared them with reports from the Japanese Adverse Drug Event Report (JADER) database to identify differences and trends.
Masami Tsuchiya, Ryohkan Funakoshi, Koichi Masuyama, Nariyasu Mano, Satoko Hori, Taku Obara   +5 more
wiley   +1 more source

Impact of melanoma histological regression on first‐line immunotherapy response in stage‐IV disease

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Jean‐Baptiste Such, Sandrine Mansard, Mélissa Zlobecki, Carole Chevenet, Céline Lambert, Marie Bachelerie, Jacques Rouanet   +6 more
wiley   +1 more source

Effectiveness and Mechanism of Cryoablation in the Treatment of Oral Mucosal Melanoma

Cancer Medicine, Volume 15, Issue 2, February 2026.
ABSTRACT Objectives To assess the effectiveness and safety of cryoablation for oral mucosal melanoma (OMM) and explore its underlying mechanisms to provide insights for precision treatment of OMM. Materials and Methods Patients diagnosed with OMM were divided into a cryoablation group and a noncryoablation therapy group.
Zhu You, Tianqi Zhang, Li Dai, Jie Wen, Mingyang Liu, Tengda Zhao, Guozhu Yin, Yihua Wu, Shizhou Zhang   +8 more
wiley   +1 more source

NCI9673 (Part B): ETCTN Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Refractory, Metastatic Squamous Cell Carcinoma of the Anal Canal. [PDF]

J Clin Oncol
Morris VK, Ciombor KK, Xiao L, Ochieng JK, Marmonti E, Polite B, Weinberg BA, Krauss JC, Hays J, Mukherjee S, Aranha O, Iqbal S, Shields T, Benson AB, Kazmi S, Lieu C, Hochster H, Whisenant J, Haymaker C, Eng C.   +19 more
europepmc   +1 more source

Adverse Renal Outcomes in Patients With Mesothelioma—A Territory‐Wide Real‐World Data

Cancer Medicine, Volume 15, Issue 2, February 2026.
ABSTRACT Introduction Advances in mesothelioma management have translated into longer patient survival and different treatment‐related side effects including nephrotoxicity. The risk of developing adverse renal outcomes in patients with mesothelioma and associated risk factors remains undefined.
Wang Chun Kwok, James Chung Man Ho, Isaac Sze Him Leung, Desmond Yat Hin Yap   +3 more
wiley   +1 more source

A Systematic Review of Ipilimumab-Induced Hypophysitis. [PDF]

Endocr Connect
Kim S, Yadav Teerupati SN, Rissardo JP, Patel P, Lai E, Byroju VV, Fornari Caprara AL.   +6 more
europepmc   +1 more source